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Abstract
Background: N-acylethanolamines (NAEs) are lipids upregulated in response to cell and tissue
injury and are involved in cytoprotection. Arachidonylethanolamide (AEA) is a well characterized
NAE that is an endogenous ligand at cannabinoid and vanilloid receptors, but it exists in small
quantities relative to other NAE types. The abundance of other NAE species, such as
palmitoylethanolamine (PEA), together with their largely unknown function and receptors, has
prompted us to examine the neuroprotective properties and mechanism of action of PEA. We
hypothesized that PEA protects HT22 cells from oxidative stress and activates neuroprotective
kinase signaling pathways.
Results: Indeed PEA protected HT22 cells from oxidative stress in part by mediating an increase
in phosphorylated Akt (pAkt) and ERK1/2 immunoreactivity as well as pAkt nuclear translocation.
These changes take place within a time frame consistent with neuroprotection. Furthermore, we
determined that changes in pAkt immunoreactivity elicited by PEA were not mediated by activation
of cannabinoid receptor type 2 (CB2), thus indicating a novel mechanism of action. These results
establish a role for PEA as a neuroprotectant against oxidative stress, which occurs in a variety of
neurodegenerative diseases.
Conclusions: The results from this study reveal that PEA protects HT22 cells from oxidative
stress and alters the localization and expression levels of kinases known to be involved in
neuroprotection by a novel mechanism. Overall, these results identify PEA as a neuroprotectant
with potential as a possible therapeutic agent in neurodegenerative diseases involving oxidative
stress.
Introduction
N-Acylethanolamines (NAEs) are endogenous lipids
involved in cell signaling and they are synthesized in
response to cellular injury [1,2]. The NAE, arachido-
nylethanolamide (AEA), is a cannabinoid exhibiting cyto-
protective properties against a wide variety of pathological
insults including excitotoxicity, oxidative stress and
hypoxia [3-10]. Cannabinoids activate the G-protein-cou-
pled cannabinoid receptors (CB1 and CB2) leading to
downregulation of PKA and activation of the ERK MAPK
pathway, a neuroprotective signaling pathway [11-18].
Furthermore, the activation of Akt by cannabinoids fur-
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ingly, concentrations of AEA in various tissues including
the brain are relatively low compared to other NAE species
such as the non-cannabinoid NAE, palmitoyleth-
anolamine (PEA) [19,20].
Some saturated and monounsaturated NAEs have been
shown to activate ERK1/2 phosphorylation pathway
through a CB1-independent mechanism [21]. Interest-
ingly, the yeast Saccharomyces cerevisiae, which does not
express cannabinoid or vanilloid receptors, synthesizes
various NAE species in response to oxidative stress [22].
This result further substantiates a non-cannabinoid recep-
tor- and a non-vanilloid receptor-mediated function for
some NAEs.
In the present study, we determined that the lipid PEA is
neuroprotective against oxidative insult. PEA treatment
can activate the ERK1/2 MAP kinase and Akt proteins as
determined by microfluorimetric measurements. Here, we
identified that PEA can increase ERK1/2 and Akt phospho-
rylation and nuclear translocation of phospho-Akt
(Ser473) (pAkt) which suggests that the neuroprotective
effects of PEA may be mediated, in part, by activation of
these kinases. Furthermore, we provide evidence that this
effect of PEA is not mediated through the activation of
CB2. The results of the present study identify PEA as a
potential therapeutic agent for the treatment of neurode-
generative diseases in which oxidative stress occurs. Fur-
thermore, PEA shares a similar mechanism of action with
other neuroprotectants providing further evidence for the
importance of kinase signaling in neuroprotection.
Materials and methods
Chemicals
Palmitoylethanolamine (PEA), JWH-015, AM-1242 and
AM-630 were purchased from Alexis Biochemicals (Swit-
zerland). Calcein-acetoxymethyl ester (calcein-AM) was
purchased from Alexis Biochemicals or EMD/Calbio-
chem. Tert-butylhydroperoxide (tBHP) was purchased
from Acros Organics (Belgium).
Cell culture
The murine hippocampal cell line HT22 was cultured as
described previously [23]. In brief, HT22 cells were grown
in Dulbecco's modified Eagle's medium (DMEM) with
high glucose and 1 mM sodium pyruvate (Mediatech), 2
mM Glutamax (Invitrogen), 5% bovine growth serum
(BGS) (Hyclone) and penicillin-streptomycin (Medi-
atech). Cultures were kept at a confluency of less than
70% during the culturing process. For immunofluores-
cence analysis, HT22 cells were plated on poly-L-lysine-
coated 12 mm coverslips overnight followed by treat-
ments as described in the text. Immunocytochemistry was
subsequently conducted as described elsewhere in detail
[23].
Assessment of cell viability
Oxidative stress was induced by exposing cells to 20 - 25
μM tBHP. The fluorimetric calcein- AM and VYBRANT
glucose-6-phosphate dehydrogenase (G-6-PD) cytotoxic-
ity assays (Invitrogen) were conducted in 96 well plates in
order to assess cell viability in a high-throughput format.
All 96 well plate assays for HT22 cell viability were con-
ducted using a cell density of 2,000 cells/well unless noted
otherwise. For the calcein-AM assay, media was removed
from plates after 16 - 20 hours of tBHP exposure followed
by replacement with Hank's balanced salt solution
(HBSS) with 2 mM CaCl2 and calcein-AM dye at a final
concentration of 4 μM for 20 minutes to load cells. Cal-
cein fluorescence was measured using a fluorimetric plate
reader (Perkin-Elmer Victor3) with the appropriate filters
(485 nm excitation and 530 nm emission). The underly-
ing mechanism is that viable cells take up the ester form
of calcein (calcein-AM) and convert it to the non-ester
form, calcein. Calcein accumulates in viable cells resulting
in elevated fluorescence. The VYBRANT G-6-PD cytotoxic-
ity assays were conducted 10 - 12 hours after tBHP expo-
sure according to the manufacturer's instructions with a
substrate reaction time of 5 - 6 hours at 37°C and read at
530 nm excitation and 560 nm emission. In principle,
non-viable cells leak their contents into the culture media
thus allowing for the assay of enzyme activity, such as G-
6-PD activity. All raw data was analyzed, normalized and
graphed in Microscoft Excel.
Immunocytochemistry after PEA treatment
HT22 cells were plated on poly-L-lysine-coated 12 mm
coverslips at 40,000 cells/ml and maintained for 24
hours. The media was removed and replaced with media
containing 100 μM PEA (or ethanol vehicle) for various
time points (as described in the results). After the PEA
exposure, the cells were rinsed and fixed with 4% parafor-
maldehyde followed by immunocytochemistry (ICC)
using polyclonal sera raised against Akt, pAkt, ERK1/2,
phospho-ERK1/2 (Thr202/Tyr204) (pERK1/2), p38 or
monoclonal rabbit anti-phospho-p38 (Thr180/Tyr182)
antibody (Cell Signaling Technology, Danvers, MA) using
a method described elsewhere [23]. After completion of
ICC and mounting, images were acquired at 20× magnifi-
cation using an Olympus IX70 fluorescence microscope.
TIFF images were analyzed in Simple PCI by selecting
three (3) background regions of interest (ROIs) followed
by nuclear then cytosolic ROIs for each cell. The nuclear
and cytosolic data was separated in Microsoft Office Excel
and graphed.
Statistics
For neuroprotection experiments (calcein-AM and
VYBRANT cytotoxicity assays), a one-way ANOVA with a
Neumann-Keuls post-hoc test was conducted using
GraphPad Prism 5.01. For immunofluorescence experi-
ments, an F-test was conducted in Microsoft ExcelPage 2 of 12
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untreated control group to determine which type of T-test
should be used for group comparisons. The mean fluores-
cence intensity from each treatment group was separately
compared to the mean fluorescence intensity of the
untreated control group using a two-sample T-test with
either equal or unequal variances. Multiple comparisons
were not done with the T-test. A P-value of less than or
equal to 0.05 was considered significant.
Results
PEA protects HT22 from oxidative stress
HT22 cells were treated with PEA (100 μM) for various
time periods to determine the therapeutic window for
PEA. Use of PEA concentrations lower than 100 μM do
not offer protection of HT22 cells from tBHP-mediated
oxidative stress and, therefore, these data are not
included. PEA treatment for 5 - 6 hours prior to overnight
(16 - 20 hour) tBHP exposure significantly protects HT22
cells from tBHP as indicated by an increase in calcein flu-
orescence and a decrease in G-6-PD activity (VYBRANT
reagent fluorescence) (Fig. 1A, B). Treatment of cells with
PEA for shorter time periods (1 - 2 h) prior to tBHP insult
offered no neuroprotection (Fig. 1C, D) while a longer
time period (12 h) prior to tBHP exposure exhibit a signif-
icant reduction in markers of cell death according to pre-
liminary data (Fig. 1E, F). This suggests that the
therapeutic window of PEA treatment before insult is crit-
ical for its neuroprotective properties.
PEA treatment increases pAkt kinase immunoreactivity 
and controls nuclear translocation by a CB2-independent 
mechanism
Exposure of HT22 cells to PEA for four hours had no sig-
nificant effect on nuclear Akt immunoreactivity (Fig. 2A),
but it resulted in a significant increase in nuclear pAkt
immunoreactivity (Fig. 2B). A six hour PEA treatment also
had the same effect (data not shown).
To determine whether or not PEA's effects on Akt phos-
phorylation and nuclear translocation required activation
of CB2, HT22 cells were treated with the CB2 agonists,
JWH-015 and AM1241, for 6 hours prior to Akt and pAkt
immunolabeling. Treatment of HT22 cells with 10 μM
JWH-015 alone had no effect on nuclear or cytosolic Akt
immunoreactivity (Fig. 3A) but it led to a decrease in
cytosolic pAkt immunoreactivity (Fig. 3B). Interestingly,
activated Akt (pAkt) has cytosolic functions distinct from
its nuclear functions [24,25]. Treatment of cells with 10
μM AM1241 alone led to a significant increase in nuclear
Akt immunoreactivity (Fig. 3A), but it had no effect on
pAkt immunoreactivity (Fig. 3B). Our data suggest that
JWH-105 fails to mimic the effects of PEA on pAkt immu-
noreactivity in HT22 cells. This suggests that PEA's ability
to increase nuclear pAkt is through a CB2-independent
mechanism.
In addition, the CB2 antagonist, AM630 was utilized to
rule out CB2 activation in PEAs effects on Akt and pAkt
(Fig. 4). Although a 6 hour treatment with PEA had no sig-
nificant effect on Akt immunoreactivity, treatment with
AM630 led to a significant increase in nuclear Akt relative
to cytosolic Akt (Fig. 4A). Interestingly, combined treat-
ment with PEA and AM630 only led to a slight increase in
nuclear Akt immunoreactivity relative to cytosolic Akt
(Fig. 4A).
A 6 hour treatment of cells with AM630 led to a significant
increase in nuclear pAkt immunoreactivity relative to
cytosolic pAkt immunoreactivity similar to that observed
for PEA-treated cells, indicating that PEAs effects were not
mediated through CB2 receptor activation (Fig. 4B). Inter-
estingly, combined treatment with PEA and AM630 led to
an increase in nuclear pAkt relative to cytosolic pAkt
immunoreactivity in part due to a decrease in cytosolic
pAkt immunoreactivity. These results suggest that altera-
tions in Akt and pAkt compartmentalization are affected
differently by PEA and AM630. These results provide evi-
dence that CB2 activation is not responsible for the
observed changes in pAkt immunoreactivity mediated by
PEA treatment in HT22 cells.
Effect of PEA treatment on MAPK and phosphorylated 
MAPK immunoreactivity
Exposure of HT22 cells to PEA for 30 minutes had no
effect on ERK1/2 immunoreactivity (Fig. 5A). Exposure of
cells to PEA for 30 minutes, however, led to a significant
increase in nuclear and cytosolic pERK1/2 immunoreac-
tivity (Fig. 5B). Exposure of cells to PEA for 60 minutes
resulted in a dramatic and significant decrease in both
nuclear and cytosolic phospho-p38 immunoreactivity
(Fig. 5C). Furthermore, treatment of HT22 cells with
JWH015 had no significant effect on ERK1/2 or pERK1/2
immunoreactivity (Fig. 6A, B). This suggests that PEAs
effects on ERK1/2 and pERK1/2 immunoreactivity are not
due to CB2 activation.
Discussion
From these studies, we conclude that PEA (at 100 μM)
protects HT22 cells from oxidative stress when cells are
pretreated for 5 - 6 hours prior to tBHP exposure (Fig. 1).
Interestingly, shorter PEA pretreatment times did not pro-
tect and PEA pretreatment for 12 hours protected cells
from tBHP insult as measured by G-6-PD activity in the
culture media (Fig. 1). These studies identify PEA as a neu-
roprotectant that is naturally synthesized in neurons.
In addition, we provide evidence that PEA treatment facil-
itates the nuclear translocation of pAkt in a neuronal cell
line by a CB2-independent mechanism (Fig. 3 and 4). Fur-
thermore, we determined that PEA leads to a rapid and
transient increase in nuclear and cytosolic pERK1/2, but
not ERK1/2 (Fig. 5). This mechanism is independent ofPage 3 of 12
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PEA pretreatment protects HT22 cells from tBHP exposureFigure 1
PEA pretreatment protects HT22 cells from tBHP exposure. (A, B), HT22 cells were pretreated with 100 μM PEA 
for 5 - 6 hours prior to an overnight (10 - 12 hour or 16 - 20 hour) tBHP exposure. PEA pretreatment led to a significant neu-
roprotection against oxidative stress as determined by an increase in calcein fluorescence (A), and a reduction in fluorescent 
product from G-6-PD in the cell culture media (B). For this study, n equals three (3) experiments. HT22 cells were pretreated 
with PEA for 1 - 2 hours (C, D) or 12 hours (E, F) prior to tBHP exposure. PEA pre-treatment for 1 - 2 hours had no effect on 
viability (E), whereas pretreatment for 12 hours reduced measured extracellular G-6-PD activity (F). A P-value of ≤ 0.05, ≤ 0.01 
and ≤ 0.001 is indicated by *, ** and ***, respectively, as determined by a Newman-Keuls multiple comparison test.
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PEA treatment of HT22 cells leads to an increase in nuclear pAkt immunoreactivityFigure 2
PEA treatment of HT22 cells leads to an increase in nuclear pAkt immunoreactivity. (A), a four (4) hour PEA 
treatment led to a significant decrease in Akt immunoreactivity but it had no effect on nuclear Akt immunoreactivity. For the 
treatment groups, n equals 50 and 66 cells for vehicle and PEA treatments, respectively. (B), a four (4) hour PEA treatment led 
to a significant increase in nuclear pAkt (red arrow) and a significant decrease in cytosolic pAkt. For the treatment groups, n 
equals 56 and 75 cells, respectively. A P-value of <0.05 and ≤ 0.01 is indicated by * and **, respectively, as determined by a two-
sample t-test. The white scale bar is 25 μm.
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The CB2 agonist AM1241, but not JWH-015, increases nuclear Akt immunoreactivityFigure 3
The CB2 agonist AM1241, but not JWH-015, increases nuclear Akt immunoreactivity. (A), Treatment of HT22 
cells with the CB2 agonist JWH-015 had no effect on nuclear Akt immunoreactivity. Treatment with AM1241, however, led to 
an increase in nuclear Akt immunoreactivity (red arrows). (B), Treatment of HT22 cells with the CB2 agonists JWH-015 and 
AM1241 had no effect on nuclear or cytosolic pAkt immunoreactivity. In fact, JWH-015 led to a reduction in pAkt immunore-
activity. For the Akt study, n equals 61, 56 and 59 cells for vehicle, JWH-015 and AM-1241 treatments, respectively. For the 
pAkt study, n equals 80, 91 and 64 cells for vehicle, JWH-015 and AM-1241 treatments, respectively. A P-value of < 0.01 and ≤ 
0.001 is indicated by ** and ***, respectively, as determined by a two-sample t-test. The white scale bar is 25 μm.
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The CB2 antagonist, AM630, alters Akt and pAkt immunoreactivity in HT22 cellsFigure 4
The CB2 antagonist, AM630, alters Akt and pAkt immunoreactivity in HT22 cells. (A), Treatment of HT22 cells 
with AM630 leads to an increase in nuclear Akt immunoreactivity (red arrow) and an increase in the nuclear over cytosolic Akt 
immunoreactivity ratio (graph) while the presence of PEA reduces this increase (graph). (B), Likewise AM630 increases nuclear 
pAkt immunoreactivity (red arrow) and increases the nuclear over cytosolic pAkt immunoreactivity ratio (graph) and while the 
inclusion of PEA reduces this effect (graph). Co-treatment of cells with both PEA and AM630 results in an increase in nuclear 
Akt (red arrow, graph). For the Akt study, n equals 50, 66, 52, 53, 62 and 65 cells for vehicle (PEA), PEA, vehicle (AM630), 
AM630, vehicle (PEA and AM630) and PEA and AM630 treatments, respectively. For the pAkt study, n equals 56, 75, 94, 78, 75 
and 89 cells for vehicle (PEA), PEA, vehicle (AM630), AM630, vehicle (PEA and AM630) and PEA and AM-630 treatments, 
respectively. A P-value of ≤ 0.05, < 0.01 and ≤ 0.001 is indicated by *, ** and ***, respectively, as determined by a two-sample 
t-test.
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PEA increases nuclear and cytosolic pERK1/2 and decreases nuclear and cytosolic phospho-p38 immunoreactivity in HT22 cells independent of CB2 activationFigure 5
PEA increases nuclear and cytosolic pERK1/2 and decreases nuclear and cytosolic phospho-p38 immunoreac-
tivity in HT22 cells independent of CB2 activation. (A), A brief, 30 minute PEA treatment of HT22 cells has no effect on 
nuclear or cytosolic ERK1/2 immunoreactivity. (B), a 30 minute PEA treatment results in a transient increase in nuclear and 
cytosolic pERK/12 immunoreactivity. In the ERK1/2 immunofluorescence experiment, n equals 24 and 34 cells for vehicle and 
PEA treatments, respectively. In the pERK1/2 immunofluorescence experiment, n equals 46 and 81 cells for vehicle and PEA 
treatments, respectively. A P-value of ≤ 0.001 is indicated by *** as determined by a two-sample t-test. (C), Treatment of HT22 
cells with PEA for 30 min. resulted in a dramatic and significant decrease in both nuclear and cytosolic phospho-p38 immuno-
reactivity. In this study, for the 30 minute treatment group, n equals 42 and 35 cells for vehicle and PEA treatments, respec-
tively. For the 60 minute treatment group, n equals 50 and 41 cells for vehicle and PEA treatments, respectively. A P-value of ≤ 
0.001 is indicated by *** as determined by a two-sample t-test.
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The CB2 agonist JWH-015 has no effect on ERK1/2 or pERK1/2 immunoreactivity in HT22 cellsFigure 6
The CB2 agonist JWH-015 has no effect on ERK1/2 or pERK1/2 immunoreactivity in HT22 cells. A brief 60 
minute treatment of HT22 cells with the CB2 agonist JWH-015 fails to significantly increase ERK1/2 immunoreactivity (A) or 
pERK1/2 immunoreactivity (B). In the ERK1/2 immunofluorescence experiment, n equals 54 and 59 cells for vehicle and JWH-
015 treatments, respectively. In the pERK1/2 immunofluorescence experiment, n equals 34 and 40 cells for vehicle and JWH-
015 treatments, respectively. Significance was determined by a two-sample t-test.
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agonist, JWH-015 (Fig. 6). In addition, we determined
that PEA exposure leads to a significant reduction in
nuclear and cytosolic phospsho-p38 immunoreactivity in
HT22 cells (Fig. 5C). These effects are within the time-
frame required to cause neuroprotection in HT22 cells.
Taken together, these data suggest that PEA activates
kinases known to be involved in neuroprotective signal-
ing, thus providing a possible mechanism by which NAEs
protect neurons.
Cannabinoids, such as AEA, exhibit neuroprotective prop-
erties against a wide variety of pathological insults includ-
ing excitotoxicity, oxidative stress and hypoxia through
the activation of CB1 [2-10]. Cannabinoids activating
CB1 and CB2 can subsequently activate the ERK1/2, p38
and JNK MAPKs in addition to Akt [14-16,26-30].
MAPKs and Akt initiate neuroprotective responses [31-
35]. For example, in HT22 cells, short-term activation of
ERK1/2 is involved in a cellular adaptive response to
glutamate toxicity [34]. In PC12 cells, H2O2 treatment
leads to the rapid phosphorylation of ERK1/2 and p38
[36]. Cannabinoid activation of CB1 and CB2 receptors
leads to downregulation of PKA and activation of the ERK
MAPK pathway, a neuroprotective signaling pathway
[14,15,26,33-35]. The data presented here provide evi-
dence that PEA, which is neuroprotective, can elevate
pERK1/2 and reduce phospho-p38 immunoreactivity in
HT22 cells providing evidence for a possible mechanism
of action for PEA mediated neuroprotection.
The activation of Akt further supports a role for cannabi-
noids as neuroprotectants [16,30]. In neurons, Akt activa-
tion results in neuroprotection by inhibiting pro-
apoptotic proteins including Bad, FOXO, GSK3α/β and
caspase-9 [32]. Akt activation can inhibit FOXO- and p53-
mediated transcription of death genes such as FasL and
Bax [17]. Activated Akt (pAkt) has also been shown to
activate NFκB- and CREB-mediated transcription leading
to protection of culture cells against serum deprivation
[37,38]. It is not clear, however, whether inhibition of
pro-apoptotic or activation of anti-apoptotic transcription
factors occurs after pAkt is translocated to the nucleus. The
nuclear translocation of Akt in response to PEA treatment
occurring within a time frame consistent with neuropro-
tection PEA suggests a possible mechanism involving
transcription of neuroprotective genes. We previously
showed that inositol 1, 4, 5-trisphosphate (IP3) receptors
located in the cytosolic compartment (endoplasmic retic-
ulum) can are phosphorylated by activated Akt thus lead-
ing to an increase in activity [24,25]. It is possible,
therefore, that PEA activation of Akt in the cytosolic com-
partment may lead to IP3 receptor phosphorylation and
activity. This activity Akt may have a role in neuroprotec-
tive signaling in addition to the nuclear functions of pAkt.
Studies in immune cells reveal that PEA has CB2 receptor-
independent effects [39]. Several NAEs including PEA lead
to increase ERK phosphorylation and AP-1 activity in
mouse JB6 epidermal cells [21]. The CB1 agonist Win
55212, however, could not stimulate ERK phosphoryla-
tion or AP-1 activation suggesting a CB1-independent
function of NAEs in cell signaling and gene transcription
[21].
Since saturated NAEs, such as PEA, do not bind CB1 and
exhibit poor affinity for CB2, we hypothesized that these
NAEs exhibit neuroprotective properties by a mechanism
independent of CB2 [40,41]. To rule out CB2-mediated
effects in PEA neuroprotective signaling, we measured the
effect of CB2 agonists on Akt/pAkt and ERK/pERK immu-
noreactivity. The CB2 agonist, JWH-015 had no effect on
nuclear Akt or pAkt immunoreactivity in HT22 cells. The
CB2 agonist AM1241, however, increased nuclear Akt
immunoreactivity, but it had no effect on pAkt immuno-
reactivity. Together, these data suggest that PEAs effect on
pAkt were not mediated through CB2 activation. Further
evidence for this comes from the observation that treat-
ment of cells with the CB2 antagonist, AM630, mimics
instead of inhibits the effects of PEA on cytosolic Akt
immunoreactivity and nuclear and cytosolic pAkt immu-
noreactivity in HT22 cells. These observations using
AM630 suggest that either AM630 inverse agonist activity
at CB2 receptors may lead to an increase in nuclear pAkt
immunoreactivity or that AM630 may have a yet
unknown receptor that alters pAkt activity upon activa-
tion. Given the reported weak partial agonist activity of
PEA at CB2 receptors [40,41] and the inverse agonist activ-
ity of AM630 at CB2 receptors [42], it is unlikely that the
similar effects between PEA and AM630 on pAkt are due
to a CB2-dependent mechanism.
The present study identifies PEA as a neuroprotectant
exerting its actions through a mechanism not involving
classical cannabinoid receptors and through signaling
pathways known to be involved in a neuroprotective
response. The present studies lay the groundwork for bet-
ter understanding the potential neuroprotective effects
that non-cannabinoid NAEs have in neurodegenerative
diseases.
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